Fatal myocardial infarction during nilotinib treatment in a 60-year-old male patient

Acta Oncologica

Volumn 49, Issue 4, 2010, Pages 523-525

  Brauchli, Yolanda B ^a   Wais, Thomas ^b   Gratwohl, Alois ^c   Heim, Dominik ^c   Schipf, Alexander ^d   Diebold, Joachim ^d   Kärhenbühl, Stephan ^c  

^a UNIVERSITY OF BASEL   (Switzerland)

^b Division of Internal Medicine   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d LUZERNER KANTONSSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CREATINE KINASE; ESCITALOPRAM; IMATINIB; NILOTINIB; TORASEMIDE; TROPONIN;

ADULT; ANGINA PECTORIS; ANXIETY; AORTA ATHEROSCLEROSIS; AUTOPSY; BODY MASS; BRONCHOPNEUMONIA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER REGRESSION; CANCER RESISTANCE; CASE REPORT; CHILL; CHRONIC MYELOID LEUKEMIA; CORONARY ARTERY ATHEROSCLEROSIS; DIARRHEA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPNEA; ECHOCARDIOGRAPHY; ERGOMETRY; EXERCISE; EYELID EDEMA; FEVER; HEART ARREST; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE FIBRILLATION; HOSPITALIZATION; HUMAN; LETTER; MALE; MULTIPLE ORGAN FAILURE; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; RESUSCITATION; RETROSTERNAL PAIN; SLEEP APNEA SYNDROME; WEAKNESS;

ANTINEOPLASTIC AGENTS; AUTOPSY; CORONARY ARTERY DISEASE; ELECTROCARDIOGRAPHY; EXERCISE TEST; FATAL OUTCOME; HEART; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 77951214472     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/02841861003691952     Document Type: Letter

References (16)

1. Garcia-Manero G, Faderl S, O'Brien S, Cortes J, Talpaz M, Kantarjian HM. Chronic myelogenous leukemia: A review and update of therapeutic strategies. Cancer 2003;98: 437-457
2. Marshall HM, Hammond JM. Treatment options in imatinibresistant chronic myelogenous leukemia. Ann Pharmacother 2008;42:259-264
3. Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma 2008;49:615-619
4. Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908-916
5. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;370:2011-2019
6. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007;7:332-344 (Pubitemid 46652481)
7. Orphanos GS, Ioannidis GN, Ardavanis AG. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol 2009;48: 964-970
8. Kantarjian H, Giles F, Wunderle L, Bhalla K, O 'Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354:2542-2551 (Pubitemid 43882350)
9. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110:3540-3546
10. le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008;111:1834 -1839.
11. Edling CE, Hallberg B. c-Kit-a hematopoietic cell essential receptor tyrosine kinase. Int J Biochem Cell Biol 2007;39: 1995-1998
12. Gibbons RJ, Balady GJ, Bricker JT, Chaitman BR, Fletcher GF, Froelicher VF, et al. ACC/AHA 2002 guideline update for exercise testing: Summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol 2002; 40:1531-1540
13. Madsen JK, Hommel E, Hansen JF. Prognostic value of an electrocardiogram at rest and exercise test in patients admitted with suspected acute myocardial infarction, in whom the diagnosis is not confi rmed. Eur Heart J 1987; 8:717-724
14. Fruergaard P, Launbjerg J, Jacobsen HL, Madsen JK. Sevenyear prognostic value of the electrocardiogram at rest and an exercise test in patients admitted for, but without, confi rmed myocardial infarction. Eur Heart J 1993;14:499-504.
15. Madsen JK, Thomsen BL, Mellemgaard K, Hansen JF. Independent prognostic risk factors for patients referred because of suspected acute myocardial infarction without confi rmed diagnosis. Prognosis after discharge in relation to medical history and non-invasive investigations. Eur Heart J 1988; 9:610-618
16. Muscholl MW, Oswald M, Mayer C, von Scheidt W. Prognostic value of 2D echocardiography in patients presenting with acute chest pain and non-diagnostic ECG for ST-elevation myocardial infarction. Int J Cardiol 2002;84:217-225